Log In
Print
BCIQ
Print
Print this Print this
 

ceftobiprole

Also known as: BAL5788 (formerly Zeftera, Zevtera)

  Manage Alerts
Collapse Summary General Information
Company Basilea Pharmaceutica AG
DescriptionBroad-spectrum cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus (MRSA)
Molecular Target
Mechanism of ActionPenicillin binding proteins (PBP) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationPneumonia
Indication DetailsTreat community-acquired pneumonia (CAP); Treat community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP); Treat hospital-acquired pneumonia (HAP); Treat nosocomial pneumonia; Treat pneumonia in the hospital setting; Treat severe pneumonia in the hospital setting
Regulatory Designation

EU - Standard Review (Treat community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP));
EU - Standard Review (Treat severe pneumonia in the hospital setting);
Switzerland - Standard Review (Treat community-acquired pneumonia (CAP));
Switzerland - Standard Review (Treat hospital-acquired pneumonia (HAP))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today